<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8105296</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">34215141</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">8105296</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pii">S2213-1582(21)00110-8</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.nicl.2021.102666</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">102666</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Clinical characteristics of schizophrenia patients in the main sample.</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Clinical characteristics of schizophrenia patients in the main sample.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Aachen-1</th><th>Albuquerque<break/>(COBRE#1)</th><th>Göttingen</th><th>Groningen</th><th>Utrecht</th><th>Total</th><th><italic>P</italic>-value<sup>1</sup></th></tr></thead><tbody><tr><td>N</td><td>13</td><td>51</td><td>27</td><td>20</td><td>10</td><td>121</td><td/></tr><tr><td>Illness duration</td><td>8.08 ± 8.66</td><td>15.54 ± 12.64</td><td>6.67 ± 7.69</td><td>9.60 ± 10.46</td><td>5.11 ± 5.30</td><td>11.03 ± 11.16</td><td align="char">0.002</td></tr><tr><td><bold>Antipsychotic treatment</bold></td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>FGA</td><td>0</td><td>3</td><td>1</td><td>2</td><td>1</td><td>7</td><td/></tr><tr><td>SGA</td><td>13</td><td>43</td><td>19</td><td>8</td><td>4</td><td>87</td><td/></tr><tr><td>FGA + SGA</td><td>0</td><td>2</td><td>5</td><td>0</td><td>0</td><td>7</td><td/></tr><tr><td>Missing</td><td>0</td><td>3</td><td>2</td><td>10</td><td>5</td><td>20</td><td/></tr><tr><td>OZP-equivalent<sup>2</sup></td><td>21.72 ± 10.05</td><td>14.84 ± 10.96</td><td>25.06 ± 11.49</td><td>14.55 ± 8.31</td><td>17.10 ± 12.42</td><td>18.81 ± 11.60</td><td align="char">0.001</td></tr><tr><td><bold>PANSS</bold></td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>FTD composite</td><td>4 (4–9)</td><td>8 (5–14)</td><td>7 (4–14)</td><td>6 (4–14)</td><td>10 (6–14)</td><td>7 (4–14)</td><td align="char">≤0.001</td></tr><tr><td>FTD positive<break/>(P2 item)</td><td>1 (1–4)</td><td>1 (1–5)</td><td>2 (1–5)</td><td>1 (1–4)</td><td>2 (1–4)</td><td>1 (1–5)</td><td align="char">0.025</td></tr><tr><td>FTD negative (items N5 + N6 + N7)</td><td>3 (3–6)</td><td>6 (3–13)</td><td>5 (3–9)</td><td>4 (3–10)</td><td>7 (4–11)</td><td>5 (3–13)</td><td align="char">≤0.001</td></tr><tr><td>Positive</td><td>14.54 ± 7.08</td><td>14.35 ± 4.45</td><td>11.67 ± 3.23</td><td>14.74 ± 5.30</td><td>17.44 ± 2.96</td><td>14.06 ± 4.80</td><td align="char">0.016</td></tr><tr><td>Negative</td><td>9.85 ± 4.04</td><td>15.12 ± 5.25</td><td>13.04 ± 4.40</td><td>13.21 ± 4.45</td><td>15.33 ± 4.56</td><td>13.78 ± 4.99</td><td align="char">0.007</td></tr><tr><td>General</td><td>24.15 ± 5.66</td><td>29.41 ± 8.12</td><td>27.81 ± 5.93</td><td>27.00 ± 8.97</td><td>31.33 ± 8.70</td><td>28.26 ± 7.71</td><td align="char">0.145</td></tr><tr><td><bold>Total</bold></td><td><bold>48.54 ± 14.64</bold></td><td><bold>58.88 ± 13.36</bold></td><td><bold>52.52 ± 10.00</bold></td><td><bold>52.11 ± 18.28</bold></td><td><bold>64.11 ± 13.82</bold></td><td><bold>55.62 ± 14.25</bold></td><td align="char"><bold>0.019</bold></td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note:</italic> Data are mean ± SD or median (range). N, number of subjects per research site; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic; PANSS, Positive and Negative Symptom Scale; FTD, formal thought disorder; OZP, olanzapine. <sup>1</sup>Statistical comparison between sites was conducted using either one-way analysis of variance (ANOVA) or Kruskal-Wallis test where appropriate. <sup>2</sup>Dosage in mg/day.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Clinical characteristics of schizophrenia patients in the main sample.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>Aachen-1</th><th>Albuquerque(COBRE#1)</th><th>Göttingen</th><th>Groningen</th><th>Utrecht</th><th>Total</th><th>P-value1</th></tr></thead><tbody><tr><td>N</td><td>13</td><td>51</td><td>27</td><td>20</td><td>10</td><td>121</td><td/></tr><tr><td>Illness duration</td><td>8.08 ± 8.66</td><td>15.54 ± 12.64</td><td>6.67 ± 7.69</td><td>9.60 ± 10.46</td><td>5.11 ± 5.30</td><td>11.03 ± 11.16</td><td align="char">0.002</td></tr><tr><td>Antipsychotic treatment</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>FGA</td><td>0</td><td>3</td><td>1</td><td>2</td><td>1</td><td>7</td><td/></tr><tr><td>SGA</td><td>13</td><td>43</td><td>19</td><td>8</td><td>4</td><td>87</td><td/></tr><tr><td>FGA + SGA</td><td>0</td><td>2</td><td>5</td><td>0</td><td>0</td><td>7</td><td/></tr><tr><td>Missing</td><td>0</td><td>3</td><td>2</td><td>10</td><td>5</td><td>20</td><td/></tr><tr><td>OZP-equivalent2</td><td>21.72 ± 10.05</td><td>14.84 ± 10.96</td><td>25.06 ± 11.49</td><td>14.55 ± 8.31</td><td>17.10 ± 12.42</td><td>18.81 ± 11.60</td><td align="char">0.001</td></tr><tr><td>PANSS</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>FTD composite</td><td>4 (4–9)</td><td>8 (5–14)</td><td>7 (4–14)</td><td>6 (4–14)</td><td>10 (6–14)</td><td>7 (4–14)</td><td align="char">≤0.001</td></tr><tr><td>FTD positive(P2 item)</td><td>1 (1–4)</td><td>1 (1–5)</td><td>2 (1–5)</td><td>1 (1–4)</td><td>2 (1–4)</td><td>1 (1–5)</td><td align="char">0.025</td></tr><tr><td>FTD negative (items N5 + N6 + N7)</td><td>3 (3–6)</td><td>6 (3–13)</td><td>5 (3–9)</td><td>4 (3–10)</td><td>7 (4–11)</td><td>5 (3–13)</td><td align="char">≤0.001</td></tr><tr><td>Positive</td><td>14.54 ± 7.08</td><td>14.35 ± 4.45</td><td>11.67 ± 3.23</td><td>14.74 ± 5.30</td><td>17.44 ± 2.96</td><td>14.06 ± 4.80</td><td align="char">0.016</td></tr><tr><td>Negative</td><td>9.85 ± 4.04</td><td>15.12 ± 5.25</td><td>13.04 ± 4.40</td><td>13.21 ± 4.45</td><td>15.33 ± 4.56</td><td>13.78 ± 4.99</td><td align="char">0.007</td></tr><tr><td>General</td><td>24.15 ± 5.66</td><td>29.41 ± 8.12</td><td>27.81 ± 5.93</td><td>27.00 ± 8.97</td><td>31.33 ± 8.70</td><td>28.26 ± 7.71</td><td align="char">0.145</td></tr><tr><td>Total</td><td>48.54 ± 14.64</td><td>58.88 ± 13.36</td><td>52.52 ± 10.00</td><td>52.11 ± 18.28</td><td>64.11 ± 13.82</td><td>55.62 ± 14.25</td><td align="char">0.019</td></tr></tbody></table></div>Note: Data are mean ± SD or median (range). N, number of subjects per research site; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic; PANSS, Positive and Negative Symptom Scale; FTD, formal thought disorder; OZP, olanzapine. 1Statistical comparison between sites was conducted using either one-way analysis of variance (ANOVA) or Kruskal-Wallis test where appropriate. 2Dosage in mg/day.</transformed-table></extracted-table></extracted-tables-set>